Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function
- 1 April 2009
- journal article
- clinical trial
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 7 (4), 552-558
- https://doi.org/10.1111/j.1538-7836.2009.03292.x
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open‐label studyJournal of Thrombosis and Haemostasis, 2006
- Fixed dosage of low‐molecular‐weight heparins causes large individual variation in coagulability, only partly correlated to body weightJournal of Thrombosis and Haemostasis, 2006
- Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvementJournal of Internal Medicine, 2005
- Laboratory monitoring of low-molecular-weight heparin therapy—part IIJournal of Thrombosis and Haemostasis, 2005
- Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairmentAmerican Heart Journal, 2004
- Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunctionJournal of Thrombosis and Haemostasis, 2004
- Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With EnoxaparinCirculation, 2004
- Effect of Renal Function on the Pharmacokinetics of Enoxaparin and Consequences on Dose AdjustmentTherapeutic Drug Monitoring, 2004
- A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical PatientsNew England Journal of Medicine, 1999
- Pharmacokinetics of a low molecular weight heparin [Fragmin®] in young and elderly subjectsThrombosis Research, 1992